Organization
Novartis AG
Topic
All Topics
People
Find news about people
Alumni
Find news on alumni of any org
Industries
Find news on a particular market
Your Contacts
Find news on your contacts
Sign up for free daily alerts on this feed:
By pressing Sign Up, you agree to our Terms of Use, Privacy Policy, and the LexisNexis Terms & Conditions

Follow

Change Feed
Novartis AG
... Novartis and Biocon, which have each had success developing biosimilars on their own, ...
... clinical trials. Prior to FORMA, he held roles of increasing responsibility at Novartis AG, most recently as senior vice president and global head of development ...
... http://media.mmm-online.com/images/2018/01/11/lizbarrettnovartisoncology_1355133.jpg Liz Barrett begins her new role as CEO of Novartis Oncology on February 1 1. Novartis tapped Liz Barrett, currently Pfizer's global ...
... It didn't take Novartis to find a world-class pharma executive to replace its outgoing oncology head. ...
... Basel - Novartis announced today the initiation of SURPASS, a head-to-head clinical trial of Cosentyx ...
... Inc., Intomics A/S, JOHNSON & JOHNSON, Laboratory Corporation of America, Merck KGaA, Novartis AG, Pfizer, Inc., QIAGEN, Quest Diagnostics, Randox Laboratories, SANOFI, Teva Pharmaceuticals Limited, ...
... a value as at 31 December 2017 of approximately GBP8 million. The Novartis triple combination programme for asthma, QVM149, continues to progress with its Phase ...
... team with résumés dotted with senior posts at Serono, Eli Lilly and Novartis to advance multifunctional anticancer drugs toward human testing. Cambridge, Massachusetts-based Elstar is ...
... devices to mapping and leveraging the genetic codes to create treatments. Recently, Novartis AG received approval from the FDA for a first of its kind ...
... with Tasigna * Approval granted under priority review and is based on Novartis trials evaluating TFR with Tasigna in both the first-line and second-line settings ...
... benefit in patients with a BRAF V600 mutation[1] Basel, December 22, 2017- Novartis announced today the US Food and Drug Administration (FDA) has accepted the ...
... will retire. As clock’s ticking for CEO Joe Jimenez’s final days with Novartis, Bruno Strigini, the drugmaker’s oncology head, will also retire—from the company and ...
... in competition with the likes of Stada and Nestlé, reports say. Meanwhile, Novartis’ Sandoz, which is feeling the burn—along with the rest of its generics ...
... Basel - Novartis announced today that Bruno Strigini, CEO Novartis Oncology has decided to retire ...
... today announced that it has appointed Joseph Jimenez, Chief Executive Officer of Novartis AG, to its Board of Directors, effective March 1, 2018. Mr. Jimenez ...
... reduce costs by $3 billion in two years. ( NYT ) 3. Novartis Oncology CEO Bruno Strigini is leaving the company and the pharmaceutical industry ...
Want to see the full history on Novartis AG? Upgrade to RelSci Pro now!
Start My Free Trial